Global Nuclear Medicine Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material to diagnose and determine the severity of or treat a variety of diseases, including many types of cancers, heart disease, gastrointestinal, endocrine, neurological disorders and other abnormalities within the body. Nuclear medicine procedures can pinpoint molecular activity within the body; they offer the potential to identify the disease in its earliest stages as well as a patient’s immediate response to therapeutic interventions.

Global Nuclear Medicine Market Segments Size & Growth:

Global Nuclear medicine market size is projected to reach approximately $XX billion by the end of 2024 with a CAGR of close to XX% from $XX billion in 2017 during the forecast timeline 2018-2024.Key parameters promoting the market growth include increasing incidents of cancer and cardiac ailments, expanding SPECT AND PET applications and growing public awareness for healthcare and so on. However, the Short half-life of radiopharmaceuticals, the high capital investment required for development and stringent regulatory guidelines are thereby hampering the market growth.

Global Nuclear Medicine Market Segments Share:

Global Nuclear Medicine Market is categorised into Diagnostics which comprise of PET market and SPECT market. By Therapeutics, The market is segregated into Alpha Emitters, Beta Emitters, Brachytherapy. By Applications, The market is segmented into PET and Spect Market. By Geography, North America is projected to dominate the Global Nuclear Medicine market, and the growth in the North America economies is mainly attributed because of huge profit margins and growth prospects, Global Nuclear Medicine Market Trends:

• The utilization of myocardial perfusion imaging increased most significantly, i.e. 250 per million population (PMP) increment annually, followed by the whole-body bone scan (176 PMP) and whole-body PET scan (100 PMP) in Taiwan during the period of 2000-2012.
• Molecular imaging using high-resolution single-photon emission computed tomography (SPECT) and positron emission tomography (PET) has advanced elegantly and has steadily gained importance in the clinical and research arenas.
• Mallinckrodt plc, a leading global speciality pharmaceutical company, and Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and development assets.

Global Nuclear Medicine Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The primary market players, such as
• Mallinckrodt
• Lantheus Medical Imaging
• Segami Corporation
• Siemens Healthcare
• Bracco Imaging S.P.A.